SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kth-342383"
 

Sökning: onr:"swepub:oai:DiVA.org:kth-342383" > Co-culture platform...

Co-culture platform for tuning of cancer receptor density allows for evaluation of bispecific immune cell engagers

Mebrahtu, Aman (författare)
KTH,Proteinteknologi
Aniander, Gustav (författare)
KTH,Proteinteknologi
Mega, Alessandro (författare)
Affibody Medical AB, Scheeles väg 2, SE-171 65 Solna, Sweden, Scheeles väg 2
visa fler...
Moradi, Mona (författare)
KTH,Proteinteknologi
Thalén, Niklas (författare)
KTH,Proteinteknologi
Gudmundsdotter, Lindvi (författare)
Affibody Medical AB, Scheeles väg 2, SE-171 65 Solna, Sweden, Scheeles väg 2
Backström Rydin, Eva (författare)
Affibody Medical AB, Scheeles väg 2, SE-171 65 Solna, Sweden, Scheeles väg 2
Sandegren, Anna (författare)
Affibody Medical AB, Scheeles väg 2, SE-171 65 Solna, Sweden, Scheeles väg 2
Frejd, Fredrik Y. (författare)
Affibody Medical AB, Scheeles väg 2, SE-171 65 Solna, Sweden, Scheeles väg 2
Rockberg, Johan (författare)
KTH,Proteinteknologi
visa färre...
 (creator_code:org_t)
Elsevier BV, 2024
2024
Engelska.
Ingår i: New Biotechnology. - : Elsevier BV. - 1871-6784 .- 1876-4347. ; 79, s. 120-126
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Cancer immunotherapy, where a patient's immune system is harnessed to eradicate cancer cells selectively, is a leading strategy for cancer treatment. However, successes with immune checkpoint inhibitors (ICI) are hampered by reported systemic and organ-specific toxicities and by two-thirds of the patients being non-responders or subsequently acquiring resistance to approved ICIs. Hence substantial efforts are invested in discovering novel targeted immunotherapies aimed at reduced side-effects and improved potency. One way is utilizing the dual targeting feature of bispecific antibodies, which have made them increasingly popular for cancer immunotherapy. Easy and predictive screening methods for activation ranking of candidate drugs in tumor contra non-tumor environments are however lacking. Herein, we present a cell-based assay mimicking the tumor microenvironment by co-culturing B cells with engineered human embryonic kidney 293 T cells (HEK293T), presenting a controllable density of platelet-derived growth factor receptor β (PDGFRβ). A target density panel with three different surface protein levels on HEK293T cells was established by genetic constructs carrying regulatory elements limiting RNA translation of PDGFRβ. We employed a bispecific antibody-affibody construct called an AffiMab capable of binding PDGFRβ on cancer cells and CD40 expressed by B cells as a model. Specific activation of CD40-mediated signaling of immune cells was demonstrated with the two highest receptor-expressing cell lines, Level 2/3 and Level 4, while low-to-none in the low-expressing cell lines. The concept of receptor tuning and the presented co-culture protocol may be of general utility for assessing and developing novel bi-specific antibodies for immuno-oncology applications.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)

Nyckelord

Expression tuning
Receptor density
Regulatory elements
Screening platform

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy